234 related articles for article (PubMed ID: 28532857)
41. The long-term survival of women with surgical stage II endometrioid type endometrial cancer.
Ayhan A; Taskiran C; Celik C; Yuce K
Gynecol Oncol; 2004 Apr; 93(1):9-13. PubMed ID: 15047207
[TBL] [Abstract][Full Text] [Related]
42. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.
Sehouli J; Koensgen D; Oskay-Ozcelik G; Mustea A
Crit Rev Oncol Hematol; 2008 Sep; 67(3):204-12. PubMed ID: 18407513
[TBL] [Abstract][Full Text] [Related]
43. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
44. Chemotherapy in endometrial cancer.
Obel JC; Friberg G; Fleming GF
Clin Adv Hematol Oncol; 2006 Jun; 4(6):459-68. PubMed ID: 16981669
[TBL] [Abstract][Full Text] [Related]
45. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E; Birkeland E; Trovik J; Werner HM; Hoivik EA; Mjos S; Krakstad C; Kusonmano K; Mauland K; Stefansson IM; Holst F; Petersen K; Oyan AM; Simon R; Kalland KH; Ricketts W; Akslen LA; Salvesen HB
Clin Cancer Res; 2013 May; 19(9):2331-41. PubMed ID: 23538402
[TBL] [Abstract][Full Text] [Related]
46. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
Plante M; Stanleigh J; Renaud MC; Sebastianelli A; Grondin K; Grégoire J
Gynecol Oncol; 2017 Aug; 146(2):240-246. PubMed ID: 28577885
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials.
Hogberg T
Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
Moreira E; Paulino E; Ingles Garces ÁH; Fontes Dias MS; Saramago M; de Moraes Lino da Silva F; Thuler LCS; de Melo AC
Med Oncol; 2018 Jan; 35(3):20. PubMed ID: 29387971
[TBL] [Abstract][Full Text] [Related]
51. High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.
Harada K; Ferdous T; Harada T; Ueyama Y
Clin Exp Med; 2017 Feb; 17(1):45-50. PubMed ID: 26590596
[TBL] [Abstract][Full Text] [Related]
52. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Matulonis UA; Huang HQ; Filiaci VL; Randall M; DiSilvestro PA; Moxley KM; Fowler JM; Powell MA; Spirtos NM; Tewari KS; Richards WE; Nakayama JM; Mutch DG; Miller DS; Matei D; Wenzel LB
Gynecol Oncol; 2022 Feb; 164(2):428-436. PubMed ID: 34903380
[TBL] [Abstract][Full Text] [Related]
53. Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Kopelman ZA; Tian C; Tumas J; Phippen NT; Tarney CM; Hope ER; Winkler SS; Jokajtys S; Kucera CW; Chan JK; Richardson MT; Kapp DS; Hamilton CA; Leath CA; Jones NL; Rocconi RP; Farley JH; Secord AA; Cosgrove CM; Powell MA; Klopp A; Walker JL; Fleming GF; Bateman NW; Conrads TP; Maxwell GL; Darcy KM
Gynecol Oncol; 2024 Apr; 183():103-114. PubMed ID: 38593674
[TBL] [Abstract][Full Text] [Related]
54. Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
Vandenput I; Capoen A; Coenegrachts L; Verbist G; Moerman P; Vergote I; Amant F
Int J Gynecol Cancer; 2011 Aug; 21(6):1071-7. PubMed ID: 21792013
[TBL] [Abstract][Full Text] [Related]
55. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
56. Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics.
Ring KL; Connor EV; Atkins KA; Ricketts W; Kashlan B; Modesitt SC
Int J Gynecol Cancer; 2013 Jun; 23(5):853-60. PubMed ID: 23552806
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
59. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
Lan C; Huang X; Cao X; Huang H; Feng Y; Huang Y; Liu J
Expert Opin Pharmacother; 2013 Apr; 14(5):535-42. PubMed ID: 23480059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
